MINOXIDIL

Minoxidil Adverse Events Reported to the FDA Over Time

How are Minoxidil adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Minoxidil, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Minoxidil is flagged as the suspect drug causing the adverse event.

Most Common Minoxidil Adverse Events Reported to the FDA

What are the most common Minoxidil adverse events reported to the FDA?

Dizziness	65 (1.85%)
Wrong Drug Administered	57 (1.62%)
Dyspnoea	56 (1.59%)
Nausea	48 (1.37%)
Tachycardia	48 (1.37%)
Headache	47 (1.34%)
Blood Pressure Increased	44 (1.25%)
Oedema Peripheral	44 (1.25%)
Hypertension	43 (1.22%)
Hypotension	42 (1.2%)
Palpitations	38 (1.08%)
	Show More
Drug Ineffective	37 (1.05%)
Heart Rate Increased	33 (.94%)
Alopecia	31 (.88%)
Myocardial Infarction	30 (.85%)
Pericardial Effusion	29 (.83%)
Swelling Face	29 (.83%)
Anxiety	27 (.77%)
Hypersensitivity	27 (.77%)
Malaise	27 (.77%)
Depression	26 (.74%)
Application Site Pruritus	24 (.68%)
Asthenia	24 (.68%)
Dermatitis Contact	24 (.68%)
Hypoaesthesia	24 (.68%)
Vomiting	24 (.68%)
Weight Increased	24 (.68%)
Eye Swelling	23 (.65%)
Pruritus	22 (.63%)
Psoriasis	22 (.63%)
Burning Sensation	21 (.6%)
Chest Discomfort	21 (.6%)
Insomnia	21 (.6%)
Skin Disorder	20 (.57%)
Underdose	18 (.51%)
Vision Blurred	18 (.51%)
Abdominal Pain	17 (.48%)
Chest Pain	17 (.48%)
Renal Failure Acute	17 (.48%)
Abdominal Distension	16 (.46%)
Auricular Swelling	16 (.46%)
Blister	16 (.46%)
Cardiac Disorder	16 (.46%)
Hair Growth Abnormal	16 (.46%)
Pleural Effusion	16 (.46%)
Tinnitus	16 (.46%)
Vertigo	16 (.46%)
Visual Impairment	16 (.46%)
Flushing	15 (.43%)
Hair Texture Abnormal	15 (.43%)
Pain	15 (.43%)
Chills	14 (.4%)
Herpes Zoster	14 (.4%)
Hyperhidrosis	14 (.4%)
Hypertrichosis	14 (.4%)
Paraesthesia	14 (.4%)
Accidental Exposure	13 (.37%)
Blood Pressure Decreased	13 (.37%)
Cerebrovascular Accident	13 (.37%)
Eczema	13 (.37%)
Skin Exfoliation	13 (.37%)
Urticaria	13 (.37%)
Condition Aggravated	12 (.34%)
Convulsion	12 (.34%)
Disturbance In Attention	12 (.34%)
Erythema	12 (.34%)
Fatigue	12 (.34%)
Feeling Abnormal	12 (.34%)
Fluid Retention	12 (.34%)
Heart Rate Irregular	12 (.34%)
Oedema	12 (.34%)
Scar	12 (.34%)
Viith Nerve Paralysis	12 (.34%)
Arrhythmia	11 (.31%)
Cardiac Failure Congestive	11 (.31%)
Death	11 (.31%)
Generalised Oedema	11 (.31%)
Visual Acuity Reduced	11 (.31%)
Acne	10 (.28%)
Arthralgia	10 (.28%)
Blood Pressure Fluctuation	10 (.28%)
Blood Pressure Inadequately Control...	10 (.28%)
Diplopia	10 (.28%)
Drug Hypersensitivity	10 (.28%)
Hair Colour Changes	10 (.28%)
Intraocular Pressure Increased	10 (.28%)
Swelling	10 (.28%)
Syncope	10 (.28%)
Wrong Technique In Drug Usage Proce...	10 (.28%)
Accidental Drug Intake By Child	9 (.26%)
Angina Pectoris	9 (.26%)
Atrial Fibrillation	9 (.26%)
Blood Creatinine Increased	9 (.26%)
Bone Pain	9 (.26%)
Depressed Mood	9 (.26%)
Dry Skin	9 (.26%)
Epistaxis	9 (.26%)
Hyponatraemia	9 (.26%)
Incorrect Route Of Drug Administrat...	9 (.26%)
Loss Of Consciousness	9 (.26%)
Pneumonia	9 (.26%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Minoxidil, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Minoxidil is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Minoxidil

What are the most common Minoxidil adverse events reported to the FDA?

Epidermal And Dermal Conditions	307 (8.74%)
Neurological	175 (4.98%)
Medication Errors	145 (4.13%)
Cardiac And Vascular Investigations	134 (3.82%)
Gastrointestinal Signs	114 (3.25%)
Skin Appendage Conditions	113 (3.22%)
Cardiac Arrhythmias	101 (2.88%)
Administration Site Reactions	90 (2.56%)
Respiratory	89 (2.53%)
Vision	68 (1.94%)
Decreased And Nonspecific Blood Pre...	66 (1.88%)
	Show More
Eye	60 (1.71%)
Cardiac Disorder Signs	59 (1.68%)
Therapeutic And Nontherapeutic Effe...	57 (1.62%)
Vascular Hypertensive	55 (1.57%)
Headaches	52 (1.48%)
Anxiety Disorders	49 (1.4%)
Infections - Pathogen Unspecified	47 (1.34%)
Coronary Artery	42 (1.2%)
Inner Ear And Viiith Cranial Nerve	41 (1.17%)
Ocular Infections, Irritations And ...	41 (1.17%)
Allergic Conditions	40 (1.14%)
Depressed Mood Disorders	36 (1.03%)
Pericardial	34 (.97%)
Electrolyte And Fluid Balance Condi...	32 (.91%)
Vascular	32 (.91%)
Central Nervous System Vascular	31 (.88%)
Physical Examination Topics	30 (.85%)
Renal Disorders	28 (.8%)
Mental Impairment	27 (.77%)
Oral Soft Tissue Conditions	25 (.71%)
Angiedema And Urticaria	24 (.68%)
Hematology Investigations	24 (.68%)
Joint	24 (.68%)
Sleep Disorders	24 (.68%)
Viral Infectious	24 (.68%)
Hepatobiliary	22 (.63%)
Myocardial	21 (.6%)
Urinary Tract Signs	21 (.6%)
Injuries	20 (.57%)
Cranial Nerve Disorders	19 (.54%)
Musculoskeletal And Connective Tiss...	18 (.51%)
Chemical Injury And Poisoning	17 (.48%)
External Ear Disorders	16 (.46%)
Immunology And Allergy	16 (.46%)
Pleural	16 (.46%)
Bone Disorders	15 (.43%)
Appetite And General Nutritional	14 (.4%)
Heart Failures	14 (.4%)
Procedural And Device Related Injur...	14 (.4%)
Renal And Urinary Tract Investigati...	14 (.4%)
Suicidal And Self-injurious Behavio...	14 (.4%)
Cornification And Dystrophic Skin	13 (.37%)
Muscle	13 (.37%)
Product Quality Issues	13 (.37%)
White Blood Cell	13 (.37%)
Bacterial Infectious	12 (.34%)
Disturbances In Thinking	12 (.34%)
Lifestyle Issues	12 (.34%)
Lower Respiratory Tract Disorders	12 (.34%)
Ocular Neuromuscular	12 (.34%)
Seizures	12 (.34%)
Bronchial Disorders	11 (.31%)
Changes In Physical Activity	11 (.31%)
Fatal Outcomes	11 (.31%)
Movement Disorders	11 (.31%)
Skin Neoplasms Malignant And Unspec...	11 (.31%)
Skin Vascular Abnormalities	11 (.31%)
Spleen, Lymphatic And Reticulendoth...	11 (.31%)
Upper Respiratory Tract Disorders	11 (.31%)
Vascular Hemorrhagic	11 (.31%)
Gastrointestinal Motility And Defec...	10 (.28%)
Neurological, Special Senses And Ps...	10 (.28%)
Anemias Nonhemolytic And Marrow Dep...	9 (.26%)
Cutaneous Neoplasms Benign	9 (.26%)
Psychiatric	9 (.26%)
Testicular And Epididymal	9 (.26%)
Therapeutic Procedures And Supporti...	9 (.26%)
Body Temperature Conditions	8 (.23%)
Metabolic, Nutritional And Blood Ga...	8 (.23%)
Musculoskeletal And Connective Tiss...	8 (.23%)
Nephropathies	8 (.23%)
Ocular Structural Change, Deposit A...	8 (.23%)
Abortions And Stillbirth	7 (.2%)
Cardiac And Vascular Disorders Cong...	7 (.2%)
Hearing	7 (.2%)
Hepatic And Hepatobiliary	7 (.2%)
Menstrual Cycle And Uterine Bleedin...	7 (.2%)
Musculoskeletal And Connective Tiss...	7 (.2%)
Tongue Conditions	7 (.2%)
Vascular Therapeutic Procedures	7 (.2%)
Cardiac Valve	6 (.17%)
Pigmentation	6 (.17%)
Platelet	6 (.17%)
Reproductive Tract	6 (.17%)
Sexual Function And Fertility	6 (.17%)
Arteriosclerosis, Stenosis, Vascula...	5 (.14%)
Coagulopathies And Bleeding Diathes...	5 (.14%)
Hematological And Lymphoid Tissue T...	5 (.14%)
Injuries By Physical Agents	5 (.14%)
Obstetric And Gynecological Therape...	5 (.14%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Minoxidil, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Minoxidil is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.